Nyxoah

Company Overview

Snapshot

Founded in January 2008 by Robert Taub, Nyxoah operates with 51–200 employees. The company has raised a total of $270.7 million across 10 funding rounds from 9 investors. In October 2024, Nyxoah secured $27 million through an At-the-Market Offering.

Business overview

Nyxoah is a medical device company specializing in hypoglossal nerve stimulation therapy for obstructive sleep apnea (OSA). The company's core product is a battery-free, leadless, minimally invasive neurostimulator designed to deliver bilateral hypoglossal nerve stimulation. This therapy targets patients with moderate to severe OSA who have not responded to conventional positive airway pressure therapy. Nyxoah operates within the Health Tech & Life Sciences sector, specifically focusing on medical devices and therapeutic treatments for sleep disorders.

Strategic signal

In October 2024, Nyxoah secured $27 million through an At-the-Market Offering, a move that signals strong investor confidence in its market strategy and product pipeline. This capital infusion is particularly significant as the company prepares for the U.S. market launch of its innovative sleep apnea device, Genio, positioning Nyxoah for accelerated commercial expansion and market penetration in a critical healthcare segment.

Company Intelligence Q&A

When did Nyxoah launch its Initial Public Offering on Euronext?

Nyxoah launched its Initial Public Offering on Euronext in September 2020, raising $100 million with a valuation of $423 million.

What significant regulatory milestone did Nyxoah achieve in January 2021?

In January 2021, Nyxoah received CE mark magnetic resonance imaging (MRI) conditional labeling for its Genio neurostimulation-based OSA therapy.

What was a key strategic partnership announced by Nyxoah in September 2023?

In September 2023, Nyxoah announced a partnership with ResMed in Germany, expanding its commercial reach for the Genio system.

What was the outcome of Nyxoah's Q3 2024 earnings call?

Nyxoah SA's Q3 2024 earnings call in November 2024 highlighted strategic advances amid financial challenges, with the company reporting a loss but topping revenue estimates.

What recent development occurred regarding the commercial use of the Genio System in the U.S.?

In October 2025, Nyxoah announced the first U.S. commercial patients were implanted with the Genio® System, leading to a rise in its shares.